328 related articles for article (PubMed ID: 25698486)
1. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.
Pan Q; Pais R; Ohandjo A; He C; He Q; Omosun Y; Igietseme JU; Eko FO
Vaccine; 2015 Apr; 33(15):1865-72. PubMed ID: 25698486
[TBL] [Abstract][Full Text] [Related]
2. Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based
Richardson S; Medhavi F; Tanner T; Lundy S; Omosun Y; Igietseme JU; Carroll D; Eko FO
Front Immunol; 2021; 12():698737. PubMed ID: 34249004
[TBL] [Abstract][Full Text] [Related]
3.
Pan Q; Zhang Q; Chu J; Pais R; Liu S; He C; Eko FO
Front Cell Infect Microbiol; 2017; 7():514. PubMed ID: 29326885
[TBL] [Abstract][Full Text] [Related]
4. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses.
Pais R; Omosun Y; Igietseme JU; Fujihashi K; Eko FO
Front Immunol; 2019; 10():1577. PubMed ID: 31333682
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
[TBL] [Abstract][Full Text] [Related]
6. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
Pal S; Tatarenkova OV; de la Maza LM
Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798
[TBL] [Abstract][Full Text] [Related]
7. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
Ekong EE; Okenu DN; Mania-Pramanik J; He Q; Igietseme JU; Ananaba GA; Lyn D; Black C; Eko FO
FEMS Immunol Med Microbiol; 2009 Mar; 55(2):280-91. PubMed ID: 19040663
[TBL] [Abstract][Full Text] [Related]
8. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
[TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
[TBL] [Abstract][Full Text] [Related]
10. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.
Eko FO; Okenu DN; Singh UP; He Q; Black C; Igietseme JU
Vaccine; 2011 May; 29(21):3802-10. PubMed ID: 21421002
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets.
Ou C; Tian D; Ling Y; Pan Q; He Q; Eko FO; He C
Int Immunopharmacol; 2013 Aug; 16(4):505-10. PubMed ID: 23669337
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine.
Ifere GO; He Q; Igietseme JU; Ananaba GA; Lyn D; Lubitz W; Kellar KL; Black CM; Eko FO
J Microbiol Immunol Infect; 2007 Jun; 40(3):188-200. PubMed ID: 17639158
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
Eko FO; Lubitz W; McMillan L; Ramey K; Moore TT; Ananaba GA; Lyn D; Black CM; Igietseme JU
Vaccine; 2003 Apr; 21(15):1694-703. PubMed ID: 12639492
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
Müller T; Becker E; Stallmann S; Waldhuber A; Römmler-Dreher F; Albrecht S; Mohr F; Hegemann JH; Miethke T
Vaccine; 2017 May; 35(21):2801-2810. PubMed ID: 28413133
[TBL] [Abstract][Full Text] [Related]
17. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
18. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
[TBL] [Abstract][Full Text] [Related]
19. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes.
Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO
FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789
[TBL] [Abstract][Full Text] [Related]
20. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
